Compare PCRX & EE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PCRX | EE |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | United States |
| Employees | N/A | 1046 |
| Industry | Biotechnology: Pharmaceutical Preparations | Oil/Gas Transmission |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2010 | 2022 |
| Metric | PCRX | EE |
|---|---|---|
| Price | $22.74 | $35.79 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | $30.25 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 515.7K | 362.3K |
| Earning Date | 04-30-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 0.96% |
| EPS Growth | ★ 107.44 | 0.79 |
| EPS | 0.07 | ★ 0.37 |
| Revenue | $541,533,000.00 | ★ $1,228,263,000.00 |
| Revenue This Year | $6.78 | $23.59 |
| Revenue Next Year | $8.54 | $24.37 |
| P/E Ratio | $336.79 | ★ $97.89 |
| Revenue Growth | 26.04 | ★ 44.26 |
| 52 Week Low | $18.80 | $21.29 |
| 52 Week High | $27.64 | $43.18 |
| Indicator | PCRX | EE |
|---|---|---|
| Relative Strength Index (RSI) | 41.55 | 55.89 |
| Support Level | $22.13 | $35.10 |
| Resistance Level | $24.20 | $43.18 |
| Average True Range (ATR) | 1.26 | 1.44 |
| MACD | -0.25 | 0.26 |
| Stochastic Oscillator | 8.81 | 80.54 |
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company's commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; and iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. In addition, it is developing PCRX-201 (enekinragene inzadenovec), a novel gene therapy vector platform for the treatment of osteoarthritis of the knee.
Excelerate Energy Inc. offers comprehensive LNG solutions by providing integrated services throughout the LNG value chain. The company delivers a full range of regasification services, including Floating Storage and Regasification Units (FSRUs), infrastructure development, and the supply of LNG and natural gas. With operational presence in several countries - Argentina, Bangladesh, Brazil, Finland, Germany, Pakistan, the United Arab Emirates (UAE), and the United States. The company generates revenue through Terminal Services, as well as from LNG, gas, and power. These revenues are derived from its vertically integrated activities in LNG sourcing, transportation, regasification, and power generation.